| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.34 | 1e-10 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.41 | 8e-10 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.3 | 3e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.19 | 4e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.27 | 5e-06 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.18 | 7e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.18 | 8e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-05 |